Onyx Pharmaceuticals, Inc. Snubbing Amgen Paves Way for 89% Premium; Pfizer Inc., Novartis AG Throw Names Into Hat

Published: Jul 03, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Onyx Pharmaceuticals has rejected Amgen's takeout offer of $120 per share in cash and said it will seek additional bidders. I believe there are five key potential suitors for Onyx, each with a unique motivation to gain control of the company's most important asset—the blood cancer drug Kyprolis.

Help employers find you! Check out all the jobs and post your resume.

Back to news